Hearing loss results from pathologic conditions that affect the hearing pathway. These can be classed as conductive, sensorineural or mixed.

Conductive hearing loss occurs when something blocks the sound from reaching the inner ear whilst sensorineural hearing loss is when sound reaches the inner ear but either fails to be translated into nerve impulses (sensory loss), or the nerve impulses are not translated to the brain (neural loss).

It should be noted that hearing loss can be temporary in some instances, such as conductive hearing loss due to infection. Hearing loss can occur in one (bilateral) or both (unilateral) ears.

This report provides the current prevalent population for Hearing Loss across 12 Major Markets (USA, Canada, France, Germany, Russia, Italy, Spain, UK, Brazil, Japan, India and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Hearing Loss have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Hearing Loss include:

  • Vertigo
  • Tinnitus
  • Hyperacusis
  • Depression

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global Hearing Loss market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Hearing Loss and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Hearing Loss prevalent population.
  • Identify sub-populations within Hearing Loss which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Hearing Loss patients.